Massachusetts' EyeGate Pharmaceuticals picked up $10 million in an IPO do-over, raising cash to support its sole clinical candidate.
Spinal cord stimulation is the med tech trend du jour, and researchers are harnessing the technology to create a noninvasive method that helps restore movement in paralyzed individuals.
Amgen, long criticized over its appetite for moonshot R&D projects, scaled back its research budget by more than 10% in the second quarter, part of a companywide effort to cut costs while advancing a make-or-break pipeline.
Amgen shocked the industry in May when it cut ties with an AstraZeneca-partnered psoriasis treatment after spotting alarming rates of suicidal thoughts among patients taking the antibody. But its former collaborator is remaining optimistic about the once-promising treatment, tentatively moving toward an FDA filing.
Abbott will buy two mitral valve replacement startups, moving it even further into med tech after a series of high-profile deals last year. It obviously sees the sector as a way for it to plan for long-term growth--since its innovative biopharma candidates went with AbbVie when the companies split in early 2013.
FibroGen's in-development treatment for anemia is still in the midst of Phase III development, but thanks to a legal loophole, the pill has made its way into the world of competitive cycling, where its red blood cell-boosting effects can give athletes an advantage.
Sanofi has gotten a bit of positive reinforcement in its efforts to revive its diabetes business in the U.S. Experimental combo med LixiLan has thrown off some promising results, hitting its primary goal in a late-stage trial.
As the diagnostics industry zeroes in on rapid point-of-care tests, a team of scientists from the Johns Hopkins University is developing an innovative smartphone diagnostic for chlamydia that could improve screening for the disease.
Sanofi's combination of a Type 2 diabetes treatment and a long-acting insulin met its main goal in a Phase III trial, the company said, setting up an FDA application later this year.
Sprint Bioscience (STO:SPRINT) has entered into a cancer research collaboration with Bayer, handing over the rights to an early-stage tumor metabolism program in return for €190 million ($210 million) in upfront and milestone payments.